Inflammatory Bowel DiseaseRichard P. MacDermott, William F. Stenson |
From inside the book
Results 1-3 of 81
Page 531
... Therapy : Retrospective Studies Author / Year Number of Patients Duration of TPN " ( days ) Length of Hospital Long ... therapy Vogel et al 197428 8 9-50 8 ( 100 % ) 4 ( 50 % ) 4-36 Additional medical therapy Eisenberg et al./197429 9 ...
... Therapy : Retrospective Studies Author / Year Number of Patients Duration of TPN " ( days ) Length of Hospital Long ... therapy Vogel et al 197428 8 9-50 8 ( 100 % ) 4 ( 50 % ) 4-36 Additional medical therapy Eisenberg et al./197429 9 ...
Page 566
... therapy with sulfasalazine at a dose of 2 g / d should be considered . Studies have suggested that 4 g / d is a more effective maintenance therapy than 2 g / d , but it is a rare patient who , when feeling well , will take that amount ...
... therapy with sulfasalazine at a dose of 2 g / d should be considered . Studies have suggested that 4 g / d is a more effective maintenance therapy than 2 g / d , but it is a rare patient who , when feeling well , will take that amount ...
Page 571
... therapy . Some clinicians have chosen to treat patients with mild Crohn's disease regardless of distribution with a course of a broad - spectrum oral an- tibiotic such as tetracycline , ampicillin , or cephalexin , especially if therapy ...
... therapy . Some clinicians have chosen to treat patients with mild Crohn's disease regardless of distribution with a course of a broad - spectrum oral an- tibiotic such as tetracycline , ampicillin , or cephalexin , especially if therapy ...
Other editions - View all
Common terms and phrases
abnormalities acid action activity addition agents alterations antibodies antigens appear associated bacterial blood cause chronic Clin clinical colonic compared complement complex component Crohn's disease cytokines cytotoxic decreased defect determined diarrhea effects enhanced epithelial cells epithelium et al evidence expression factor findings function Gastroenterology genes genetic granulomas growth human immune immune response Immunol immunologic important incidence increased induced infection inflammation inflammatory bowel disease inhibition initially injury intestinal involved isolated lamina propria lesions leukocyte levels lymphocytes macrophages markers mast cells mechanisms mediators mononuclear mucin mucosal Nature neutrophils normal observed occur patients population possible potential present production prostaglandin protein rates recent receptor regulation relatives release reported response risk role schistosomiasis secretion secretory serum shown specific stimulation studies suggest T-cell tissue ulcerative colitis vitro